Solid pharmaceutical tablet
US-2024226038-A9 · Jul 11, 2024 · US
Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
US9205083B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9205083-B2 |
| Application number | US-201414554988-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2014 |
| Priority date | Nov 5, 2013 |
| Publication date | Dec 8, 2015 |
| Grant date | Dec 8, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of increasing the metabolic lifetime of dextromethorphan, comprising co-administering erythrohydroxybupropion or bupropion with dextromethorphan to a human being once or twice a day for at least eight consecutive days, wherein erythrohydroxybupropion or bupropion is administered in an amount that results in an AUC 0-12 of erythrohydroxybupropion in the human being, on day 8, that is at least about 200 ng·hr/mL, wherein the human being is an e…
Assignees
Inventors
Classifications
- A61K31/485Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9205083B2 cover?
- This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydr…
- Who is the assignee on this patent?
- Antecip Bioventures Ii Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/485. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).